Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089206 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
A Phase 2 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00089206: Completed Phase 2 study, sponsored by University of Virginia.
NCT00089206 is a Phase 2 study that has completed, run by University of Virginia. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089206, a Phase 2 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL multi-epitope melanoma peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2002-08 |
| Phase | Phase 2 |
What the finished NCT00089206 record still lists
NCT00089206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which sargramostim is the first listed.
NCT00089206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089206 about?
NCT00089206 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
What is the current status of trial NCT00089206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2002-08.
What interventions are being tested in trial NCT00089206?
The interventions under investigation include: sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089206?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00089206's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia